Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 31,379 Shares

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 31,379 shares of the firm's stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $986,555.76. Following the sale, the chief executive officer directly owned 738,809 shares in the company, valued at $23,228,154.96. This represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.57 on Tuesday. Twist Bioscience Corporation has a 12-month low of $24.07 and a 12-month high of $55.33. The stock has a market capitalization of $1.91 billion, a P/E ratio of -21.77 and a beta of 2.43. The firm's 50-day moving average is $29.05 and its two-hundred day moving average is $31.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Evercore ISI decreased their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 7th. Stephens assumed coverage on shares of Twist Bioscience in a research note on Monday. They set an "overweight" rating and a $41.00 price target on the stock. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.80.

View Our Latest Stock Analysis on TWST

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after buying an additional 302 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Twist Bioscience during the second quarter valued at approximately $97,000. CWM LLC lifted its position in Twist Bioscience by 61.4% during the third quarter. CWM LLC now owns 4,331 shares of the company's stock valued at $122,000 after buying an additional 1,648 shares in the last quarter. Finally, Bayforest Capital Ltd lifted its position in Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after buying an additional 1,604 shares in the last quarter.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories

• Five stocks we like better than Twist Bioscience
• How to Capture the Benefits of Dividend Increases
• Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate
• Top Biotech Stocks: Exploring Innovation Opportunities
• The Best Local Butchers for Thanksgiving [2025 Survey]
• Stock Analyst Ratings and Canadian Analyst Ratings
• $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].